HighTower Advisors LLC Boosts Stake in GSK plc (NYSE:GSK)

HighTower Advisors LLC lifted its position in GSK plc (NYSE:GSKFree Report) by 7.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 375,438 shares of the pharmaceutical company’s stock after buying an additional 25,662 shares during the period. HighTower Advisors LLC’s holdings in GSK were worth $13,622,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Fisher Asset Management LLC boosted its stake in shares of GSK by 4.3% in the 2nd quarter. Fisher Asset Management LLC now owns 13,824,592 shares of the pharmaceutical company’s stock worth $492,994,000 after buying an additional 571,088 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in GSK by 5.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,292,913 shares of the pharmaceutical company’s stock worth $437,383,000 after purchasing an additional 673,419 shares during the period. Arrowstreet Capital Limited Partnership raised its holdings in GSK by 32.5% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 9,621,370 shares of the pharmaceutical company’s stock worth $419,107,000 after purchasing an additional 2,362,274 shares during the period. Royal Bank of Canada raised its holdings in GSK by 255.5% in the 2nd quarter. Royal Bank of Canada now owns 7,690,026 shares of the pharmaceutical company’s stock worth $274,071,000 after purchasing an additional 5,526,736 shares during the period. Finally, Goldman Sachs Group Inc. raised its holdings in GSK by 48.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 7,113,039 shares of the pharmaceutical company’s stock worth $309,844,000 after purchasing an additional 2,316,204 shares during the period. 13.53% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on GSK shares. Morgan Stanley started coverage on GSK in a report on Tuesday, January 23rd. They issued an “equal weight” rating on the stock. Jefferies Financial Group raised GSK from a “hold” rating to a “buy” rating in a report on Wednesday, January 3rd. Finally, StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a report on Wednesday, November 1st. One analyst has rated the stock with a sell rating, one has given a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, GSK currently has a consensus rating of “Moderate Buy”.

View Our Latest Report on GSK

GSK Price Performance

NYSE:GSK opened at $41.07 on Tuesday. The company has a quick ratio of 0.70, a current ratio of 0.95 and a debt-to-equity ratio of 1.27. The business’s 50-day simple moving average is $38.60 and its two-hundred day simple moving average is $36.70. The stock has a market cap of $84.49 billion, a PE ratio of 13.64, a P/E/G ratio of 1.84 and a beta of 0.64. GSK plc has a 52 week low of $33.20 and a 52 week high of $42.21.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, April 11th. Shareholders of record on Friday, February 23rd will be issued a dividend of $0.3564 per share. The ex-dividend date is Thursday, February 22nd. This is a boost from GSK’s previous quarterly dividend of $0.34. This represents a $1.43 dividend on an annualized basis and a yield of 3.47%. GSK’s dividend payout ratio (DPR) is currently 46.51%.

About GSK

(Free Report)

GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Featured Stories

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK plc (NYSE:GSKFree Report).

Institutional Ownership by Quarter for GSK (NYSE:GSK)

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.